Axillary lymphadenopathy at the time of COVID-19 vaccination : ten recommendations from the European Society of Breast Imaging (EUSOBI)
(2021) In Insights into Imaging 12(1).- Abstract
Unilateral axillary lymphadenopathy is a frequent mild side effect of COVID-19 vaccination. European Society of Breast Imaging (EUSOBI) proposes ten recommendations to standardise its management and reduce unnecessary additional imaging and invasive procedures: (1) in patients with previous history of breast cancer, vaccination should be performed in the contralateral arm or in the thigh; (2) collect vaccination data for all patients referred to breast imaging services, including patients undergoing breast cancer staging and follow-up imaging examinations; (3) perform breast imaging examinations preferentially before vaccination or at least 12 weeks after the last vaccine dose; (4) in patients with newly diagnosed breast cancer, apply... (More)
Unilateral axillary lymphadenopathy is a frequent mild side effect of COVID-19 vaccination. European Society of Breast Imaging (EUSOBI) proposes ten recommendations to standardise its management and reduce unnecessary additional imaging and invasive procedures: (1) in patients with previous history of breast cancer, vaccination should be performed in the contralateral arm or in the thigh; (2) collect vaccination data for all patients referred to breast imaging services, including patients undergoing breast cancer staging and follow-up imaging examinations; (3) perform breast imaging examinations preferentially before vaccination or at least 12 weeks after the last vaccine dose; (4) in patients with newly diagnosed breast cancer, apply standard imaging protocols regardless of vaccination status; (5) in any case of symptomatic or imaging-detected axillary lymphadenopathy before vaccination or at least 12 weeks after, examine with appropriate imaging the contralateral axilla and both breasts to exclude malignancy; (6) in case of axillary lymphadenopathy contralateral to the vaccination side, perform standard work-up; (7) in patients without breast cancer history and no suspicious breast imaging findings, lymphadenopathy only ipsilateral to the vaccination side within 12 weeks after vaccination can be considered benign or probably-benign, depending on clinical context; (8) in patients without breast cancer history, post-vaccination lymphadenopathy coupled with suspicious breast finding requires standard work-up, including biopsy when appropriate; (9) in patients with breast cancer history, interpret and manage post-vaccination lymphadenopathy considering the timeframe from vaccination and overall nodal metastatic risk; (10) complex or unclear cases should be managed by the multidisciplinary team.
(Less)
- author
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- COVID-19 vaccines, Lymphadenopathy, Magnetic resonance imaging, Mammography, Ultrasonography (breast)
- in
- Insights into Imaging
- volume
- 12
- issue
- 1
- article number
- 119
- publisher
- Springer
- external identifiers
-
- pmid:34417642
- scopus:85113190235
- ISSN
- 1869-4101
- DOI
- 10.1186/s13244-021-01062-x
- language
- English
- LU publication?
- yes
- id
- 50266677-be30-4b53-9e77-85c82b4e8f88
- date added to LUP
- 2021-09-07 13:19:41
- date last changed
- 2024-04-20 10:46:24
@article{50266677-be30-4b53-9e77-85c82b4e8f88,
abstract = {{<p>Unilateral axillary lymphadenopathy is a frequent mild side effect of COVID-19 vaccination. European Society of Breast Imaging (EUSOBI) proposes ten recommendations to standardise its management and reduce unnecessary additional imaging and invasive procedures: (1) in patients with previous history of breast cancer, vaccination should be performed in the contralateral arm or in the thigh; (2) collect vaccination data for all patients referred to breast imaging services, including patients undergoing breast cancer staging and follow-up imaging examinations; (3) perform breast imaging examinations preferentially before vaccination or at least 12 weeks after the last vaccine dose; (4) in patients with newly diagnosed breast cancer, apply standard imaging protocols regardless of vaccination status; (5) in any case of symptomatic or imaging-detected axillary lymphadenopathy before vaccination or at least 12 weeks after, examine with appropriate imaging the contralateral axilla and both breasts to exclude malignancy; (6) in case of axillary lymphadenopathy contralateral to the vaccination side, perform standard work-up; (7) in patients without breast cancer history and no suspicious breast imaging findings, lymphadenopathy only ipsilateral to the vaccination side within 12 weeks after vaccination can be considered benign or probably-benign, depending on clinical context; (8) in patients without breast cancer history, post-vaccination lymphadenopathy coupled with suspicious breast finding requires standard work-up, including biopsy when appropriate; (9) in patients with breast cancer history, interpret and manage post-vaccination lymphadenopathy considering the timeframe from vaccination and overall nodal metastatic risk; (10) complex or unclear cases should be managed by the multidisciplinary team.</p>}},
author = {{Schiaffino, Simone and Pinker, Katja and Magni, Veronica and Cozzi, Andrea and Athanasiou, Alexandra and Baltzer, Pascal A.T. and Camps Herrero, Julia and Clauser, Paola and Fallenberg, Eva M. and Forrai, Gábor and Fuchsjäger, Michael H. and Helbich, Thomas H. and Kilburn-Toppin, Fleur and Kuhl, Christiane K. and Lesaru, Mihai and Mann, Ritse M. and Panizza, Pietro and Pediconi, Federica and Pijnappel, Ruud M. and Sella, Tamar and Thomassin-Naggara, Isabelle and Zackrisson, Sophia and Gilbert, Fiona J. and Sardanelli, Francesco}},
issn = {{1869-4101}},
keywords = {{COVID-19 vaccines; Lymphadenopathy; Magnetic resonance imaging; Mammography; Ultrasonography (breast)}},
language = {{eng}},
number = {{1}},
publisher = {{Springer}},
series = {{Insights into Imaging}},
title = {{Axillary lymphadenopathy at the time of COVID-19 vaccination : ten recommendations from the European Society of Breast Imaging (EUSOBI)}},
url = {{http://dx.doi.org/10.1186/s13244-021-01062-x}},
doi = {{10.1186/s13244-021-01062-x}},
volume = {{12}},
year = {{2021}},
}